Chiesi Agrees to Buy KalVista Pharmaceuticals for $1.9 Billion
Chiesi Farmaceutici SpA agreed to acquire US-listed KalVista Pharmaceuticals Inc. for about $1.9 billion in its biggest acquisition to date, expanding the Italian company’s rare immunology portfolio.
ORIGINAL SOURCE →via Bloomberg Markets
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · IT
- [CONFLICT] Fenerbahçe'den gönderilen Domenico Tedesco'ya İtalya'dan talip çıktı!
- [CONFLICT] Italian convicted of adultery in Egypt amid custody battle
- [CONFLICT] İtalya'da siyasi kriz: 'Bunga bunga' partilerinde fuhuşa aracılık eden kadının affı tartışılıyor
- [SPORTS] İtalyan basınında Semih Kılıçsoy şaşkınlığı: 'Sana ne oldu?'
- [CONFLICT] Armani Posts 2025 Profit Rise as Higher-End Lines Lift Results
- [CONFLICT] CVC mulls $9bn bid for Italian fintech Nexi